I wrote yesterday about how I reconcile PED use and the Hall of Fame. I’ve written a lot about Bert Blyleven and the Hall of Fame. Say, how can those things go together?
Via the Jonah Keri Podcast, of course. Jonah has been talking to some serious heavyweights this week, and the other day Blyleven gave Jonah a half hour of his time. It’s all worth listening to, but I think the most interesting part is when they talk about steroid users and the Hall. Blyleven’s take? Let McGwire, Bonds and Clemens in. His rationale (more or less) is that a lot of guys were taking and they all didn’t become Hall of Famers, so why degrade the accomplishments of the ones who did? This is a rough approximation of my own stance: sure, guys used PEDs, but it’s not like that prevents us from distinguishing them from other players and recognizing their greatness. At least if we don’t take a blanket “no PED users in the Hall” approach. Which I think is extremely problematic.
Not that Blyleven and I agree on everything. He would change his mind on Bonds or Clemens if they were to be convicted in their respective criminal prosecutions. Hard to say if he thinks that’s because that would officially make them criminals and thus disqualify them on moral grounds or, alternatively, if it would merely remove some extant doubt from his mind about what they did while they played. Bert is also part of the “release all the names” club which, as I have argued is simply wrong.
But however he comes down, it’s a good interview and a good window on how hard it is to figure out what to do with the Hall of Fame in the wake of the steroid era.
Giants’ right-hander Mark Melancon is considering surgery for an undisclosed injury, the pitcher told reporters prior to Friday’s game against the Phillies. Melancon did not divulge the exact location of the injury, but revealed that it had been plaguing him off and on since the 2012 season and was a separate issue from the right pronator strain that kept him sidelined through much of July and August. Giants’ head athletic trainer Dave Groeschner called the injury day-to-day and has not revealed a timetable for the right-hander’s return, should surgery become necessary.
Melancon, 32, has struggled to replicate the sparkling pitching line he produced with the Pirates and Nationals in 2016. He’s toting a 3.80 ERA through 25 appearances with San Francisco, flanked by a 1.1 BB/9 and 7.6 SO/9 over 23 2/3 innings. His season has been significantly shortened after multiple trips to the disabled list for a right forearm strain, and while he looked to be in line to resume his closing duties this week, the Giants will likely play it safe with the veteran righty to keep him from compromising his health in 2018.
Although the injury doesn’t appear to be severe in nature, it’s clearly intensified over the last few months. Per MLB.com’s Chris Haft, Melancon said he’s “had discomfort every day this season,” though he hopes to continue pitching through the remainder of 2017. The Giants aren’t on the verge of contending by any stretch of the imagination, but a solid end to the 2017 season could help Melancon make some headway as he looks to reclaim his status as the team’s closer next spring.
What happens when an irresistible force meets an immovable object? Just ask Javier Baez, who tracked down a sizzling 106-MPH ground ball from Jose Bautista on Friday afternoon. The defensive gem helped preserve the Cubs’ three-run lead in the top of the ninth inning, paving the way for Wade Davis‘ 25th save of the season.
Baez also impressed at the plate, collecting an RBI single in the second inning before getting tagged out at home by Miguel Montero on a convoluted 9-6-3-6-2 putout. He returned in the eighth inning to pester Tim Mayza and cleared the left field hedge with a 409-foot, two-run blast for his 20th home run of the year. With the win, the Cubs improved to 64-57 and now hold a scant 1.5-game lead over the Brewers in the NL Central.